Release date:2016-06-06  Release:

Yin, Lifang

Professor of pharmaceutics

School of Pharmacy

Phone: 86-25-83271018

Email: lifangyin_@163.com

Research Summary

Professor Yin focused on the research and developmentof new dosage forms, especially was interested in scale up of sustained release preparations such modified release tablets and pellets. And more than 20 products developed by her group were approved for clinical trials or marketing.Professor Yin hosted or participated in many national or provincial projects including 5 projects from the Creation of Major New Drugs national major projects of National Ministry of Science and Technology, the Social Development Projects of Jiangsu Science and Technology Department and some project founded by National Natural Science Foundation. Dr. Yin is the author of over 50 manuscripts and over 26 patents worldwide (7 issued and 3 transferred).


1999       Ph.D., pharmacokinetics, China pharmaceutical university

1994       M.S., pharmaceuticsChina pharmaceutical university

1990       B.S., pharmaceuticsChina pharmaceutical university

Academic Experience

2011-      Professor of pharmaceutics, China pharmaceutical university

2010-2012  Postdoctoral FellowPeaking university

2007-2011  Associate professor of pharmaceuticsChina pharmaceutical university

2000-2007  LecturerChina pharmaceutical university

Awards and Honors

2015      Outstanding contributions to Nanjingmiddle-aged and young experts, Nanjing Municipal Government

2013       The “333” High Level Talents Cultivation Project of Jiangsu Province, Jiangsu Provincial People’s Government

2009      Second Prize, for Science & Technology Progress Awards of Jiangsu, Jiangsu Provincial People’s Government

2008      New Century Excellent Talents of the Ministry of Education, Ministry of Education


  1. Li Y, Wu Z, He W, Qin C, Yao J, Zhou J, Yin L*.Globular Protein-Coated Paclitaxel Nanosuspensions: Interaction Mechanism, lobular protein-coated Paclitaxel nanosuspensions: interaction mechanism, direct cytosolic delivery, and significant improvement in pharmacokinetics.Mol Pharm. 2015, 12(5): 1485-500.  (IF= 4.384)

  2. He W, Yang K, Fan L, Lv Y, Jin Z, Zhu S, Qin C, Wang Y,Yin L*.Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability. Int J Pharm. 2015, 495(1):9-18.IF=3.650

  3. Shi C, Cao H, He W, Gao F, Liu Y, Yin L*. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.Biomed Pharmacother. 2015, 73:48-57.IF=2.303

  4. He W, Wu M, Huang S, Yin L*. Matrix tablets for sustained release of repaglinide: Preparation, pharmacokinetics and hypoglycemic activity in beagle dogs. Int J Pharm. 2015, 478(1):297-307.IF=3.650

  5. He W, Jin Z, Lv Y, Cao H, Yao J, Zhou J, Yin L*.  Shell-crosslinked hybrid nanoparticles for direct cytosolic delivery for tumor therapy. Int J Pharm. 2015, 478(2):762-72.IF=3.650

  6. He W, Lv Y, Zhao Y, Xu C, Jin Z, Qin C, Yin L*. Core–shell structured gel-nanocarriers for sustained drug release and enhanced antitumor effect. Int J Pharm. 2015,484(1-2):163-71.IF=3.650

  7. He W, Huang S, Zhou C, Cao L, Yao J, Zhou J, Wang G, Yin L*.Bilayer matrix tablets for prolonged actions of metformin hydrochloride and repaglinide.AAPS PharmSciTech. 2015,16(2):344-53.IF=1.641

  8. Qin C, He B, Dai W, Lin Z, Zhang H, Wang X, Wang J, Zhang X, Wang G, Yin L*, Zhang Q*.The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3.Biomaterials. 2014, 35(22):5908-20.IF= 8.557

  9. Qin C, He W, Zhu C, Wu M, Jin Z, Zhang Q, Wang G, Yin L*.Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet.Int J Pharm. 2014,466(1-2):276-85.IF=3.650